Substance-use disorders in adolescents and adults with ADHD: Focus on treatment

Neuropsychiatry

Volumn 2, Issue 4, 2012, Pages 301-312

  Wilens, Timothy E ^a   Morrison, Nicholas R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATOMOXETINE; COCAINE; METHADONE; METHYLPHENIDATE; PLACEBO; VENLAFAXINE;

ABSTINENCE; ALCOHOLISM; ATTENTION DEFICIT DISORDER; CIGARETTE SMOKING; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED DRUG RELEASE; DISEASE SEVERITY; DRUG DEPENDENCE; DSM-IV; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PEER REVIEW; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE;

EID: 84876509435     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.12.39     Document Type: Review

References (72)

1. Merikangas KR, He JP, Burstein M et al. Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication - Adolescent Supplement (NCS-A). J. Am. Acad. Child Adolesc. Psychiatry 49(10), 980-989 (2010).
2. Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 163(4), 716-723 (2006). (Pubitemid 44464584)
3. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. Am. J. Psychiatry 164(6), 942-948 (2007). (Pubitemid 46972911)
4. Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad. Med. 122(5), 97-109 (2010).
5. Kessler RC. The epidemiology of dual diagnosis. Biol. Psychiatry 56(10), 730-737 (2004). (Pubitemid 39539830)
6. Wilens T. Attention-deficit/hyperactivity disorder and the substance-use disorders: the nature of the relationship, subtypes at risk and treatment issues. In: Psychiatric Clinics of North America. Spencer T (Ed.). Saunders Press, PA, USA, 283-301 (2004). (Pubitemid 38452768)
7. Frodl T. Comorbidity of ADHD and substance-use disorder (SUD): a neuroimaging perspective. J. Atten. Disord. 14(2), 109-120 (2010).
8. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr. Psychiatry 34(2), 75-82 (1993). (Pubitemid 23125565)
9. Levin FR, Evans SM. Diagnostic and treatment issues in comorbid substance abuse and adult attention-deficit hyperactivity disorder. Psychiatry Ann. 31(5), 303-312 (2001). (Pubitemid 33742450)
10. McAweeney M, Rogers NL, Huddleston C, Moore D, Gentile JP. Symptom prevalence of ADHD in a community residential substance abuse treatment program. J. Atten. Disord. 13(6), 601-608 (2010).
11. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/ hyperactivity disorder and future substance-use disorders: comparative meta-analyses. J. Am. Acad. Child Adolesc. Psychiatry 50(1), 9-21 (2011). This recent meta-analyses of 13 studies suggest childhood ADHD is associated with alcohol-and drug-use disorders in adulthood, and with nicotine use by middle adolescence.
12. Biederman J, Wilens T, Mick E et al. Is ADHD a risk for psychoactive substanceuse disorder? Findings from a four year follow-up study. J. Am. Acad. Child Adolesc. Psychiatry 36, 21-29 (1997). (Pubitemid 27024224)
13. Katusic SK, Barbaresi WJ, Colligan RC, Weaver A, Mrazek DA, Jacobsen SJ. Substance abuse among ADHD cases: a population-based birth cohort study. Presented at: Pediatric Academic Society Annual Meeting. Seattle, WA, USA, 3-6 May 2003.
14. Molina B, Pelham W. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J. Abnorm. Child Psycho. 112(3), 497-507 (2003). (Pubitemid 36959375)
15. Brook DW, Brook JS, Zhang C, Koppel J. Association between attention-deficit/hyperactivity disorder in adolescence and substance-use disorders in adulthood. Arch. Pediatr. Adolesc. Med. 164(10), 930-934 (2010).
16. Wilens T, Martelon M, Joshi G et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 50(6), 543-553 (2011).
17. Wilens TE, Martelon M, Fried R, Petty C, Bateman C, Biederman J. Do executive function deficits predict later substance-use disorders among adolescents and young adults? J. Am. Acad. Child Adolesc. Psychiatry 50(2), 141-149 (2011).
18. Kollins SH. ADHD, substance-use disorders, and psychostimulant treatment: current literature and treatment guidelines. J. Atten. Disord. 12(2), 115-125 (2008).
19. Vitiello B. Long-term effects of stimulant medications on the brain: possible relevance to the treatment of attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 11(1), 25-34 (2001). (Pubitemid 32295180)
20. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J. Child Adolesc. Psychopharmacol. 15(5), 764-776 (2005). (Pubitemid 41567148)
21. Mannuzza S, Klein RG, Truong NL et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am. J. Psychiatr. 165(5), 553-555 (2008).
22. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J. Am. Acad. Child Adolesc. Psychiatry 45(4), 408-414 (2006). (Pubitemid 43675545)
23. Simkin DR. Adolescent substance-use disorders and comorbidity. Pediatr. Clin. N. Am. 49(2), 463-477 (2002).
24. Wilens T, Faraone S, Biederman J, Gunawardene S. Does stimulant therapy of ADHD beget later substance abuse: a meta-analytic review of the literature. Pediatrics 11(1), 179-185 (2003). (Pubitemid 36071051)
25. Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance-use disorders and conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 37(3), 331-332 (1998). (Pubitemid 28101232)
26. Wilens T. Alcohol and other drug use and attention deficit/hyperactivity disorder. Alcohol Health Res. World 22(2), 127-130 (1998). (Pubitemid 128684646)
27. Levin FR, Evans SM, Kleber HD. Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder. Psychiatry Serv. 50(8), 1001-1003 (1999). (Pubitemid 29365359)
28. Safren SA, Sprich S, Mimiaga MJ et al. Cognitive behavioral therapy vs relaxation with educational support for medicationtreated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 304(8), 875-880 (2010).
29. Solanto MV, Marks DJ, Wasserstein J et al. Efficacy of meta-cognitive therapy for adult ADHD. Am. J. Psychiatry 167(8), 958-968 (2010).
30. Riggs PD, Winhusen T, Davies RD et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance-use disorders. J. Am. Acad. Child Adolesc. Psychiatry 50(9), 903-914 (2011). This multisite trial of osmotic-release oral system methylphenidate failed to demonstrate greater efficacy than placebo for ADHD or a reduction in substance use, highlighting the importance of examining the role of cognitive behavioral therapy for those with ADHD and substance-use disorder.
31. Thurstone C, Riggs PD, Salomonsen-Sautel S, Mikulich-Gilbertson SK. Randomized, controlled trial of atomoxetine for attentiondeficit/hyperactivity disorder in adolescents with substance-use disorder. J. Am. Acad. Child Adolesc. Psychiatry 49(6), 573-582 (2010).
32. Schubiner H, Saules KK, Arfken CL et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp. Clin. Psychopharmacol. 10(3), 286-294 (2002). (Pubitemid 34919937)
33. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 81(2), 137-148 (2006). (Pubitemid 41821797)
34. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 87(1), 20-29 (2007). (Pubitemid 46074379)
35. Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend. 108(1-2), 130-133 (2010).
36. Winhusen TM, Somoza EC, Brigham GS et al. Impact of attention-deficit/ hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebocontrolled trial. J. Clin. Psychiatry 71(12), 1680-1688 (2010). Substance-use disorders in adolescents & adults with ADHD: focus on treatment Review
37. Vansickel AR, Stoops WW, Glaser PE, Poole MM, Rush CR. Methylphenidate increases cigarette smoking in participants with ADHD. Psychopharmacology (Berl.) 218(2), 381-390 (2011).
38. Riggs P. Multi-site of OROS-MPH for ADHD in substance abusing adolescents. Presented at: The Scientific Proceedings of the 56th Annual Meeting for the American Academy of Child and Adolescent Psychiatry.
39. October-1 November, Honolulu, HI, USA (2009).
40. Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. 29(7), 1439-1464 (2004). (Pubitemid 39172183)
41. Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 67(2), 149-156 (2002). (Pubitemid 34722402)
42. Wilens TE, Adler LA, Weiss MD et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol-use disorders. Drug Alcohol Depend. 96(1-2), 145-154 (2008). This placebo-controlled trial demonstrates clinically significant ADHD improvement but inconsistent effects on drinking behavior in recently abstinent alcoholics.
43. Adler L, Guida F, Irons S, Shaw D. Open label pilot study of atomoxetine in adults with ADHD and substance-use disorder. J. Dual. Diagnosis 6(3-4), 196-207 (2010).
44. Adler L, Wilens T, Zhang S et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am. J. Addict. 18(5), 393-401 (2009).
45. Wilens T, Monuteaux M, Snyder L, Moore H, Gignac M. The clinical dilemma of using medications in substance abusing adolescents and adults with ADHD: what does the literature tell us? J. Child Adolesc. Psychopharmacol. 15(5), 787-798 (2005). (Pubitemid 41567150)
46. Biederman J, Mick E, Prince J et al. Systematic chart review of the pharmacologic treatment of comorbid attention deficit hyperactivity disorder in youth with bipolar disorder. J. Child Adolesc. Psychopharmacol. 9(4), 247-256 (1999). (Pubitemid 30005079)
47. Findling RL, Short EJ, McNamara NK et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 46(11), 1445-1453 (2007). (Pubitemid 351338965)
48. Wilens TE, Adler LA, Adamson J et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J. Am. Acad. Child Adolesc. Psychiatry 47(1), 21-31 (2008). Highlights both the motivations of those who misuse and divert stimulants and the ADHD populations at higher-risk for abusing stimulant medications.
49. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 99(1), 96-106 (2005).
50. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 26(10), 1501-1510 (2006). (Pubitemid 44521735)
51. Janusis GM, Weyandt LL. An exploratory study of substance use and misuse among college students with and without ADHD and other disabilities. J. Atten. Disord. 14(3), 205-215 (2010).
52. McCabe SE, Boyd CJ. Sources of prescription drugs for illicit use. Addict. Behav. 30(7), 1342-1350 (2005). (Pubitemid 40967022)
53. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst. Use Misuse 39(7), 1095-1116 (2004). (Pubitemid 39163121)
54. Spencer TJ, Biederman J, Ciccone PE et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. Am. J. Psychiatry 163(3), 387-395 (2006). (Pubitemid 44469379)
55. Parasrampuria D, Schoedel K, Schuller R et al. Abuse potential of OROS methylphenidate versus immediate-release methylphenidate and placebo. Presented at: The American Academy of Child and Adolescent Psychiatry/Canadian Academy of Child and Adolescent Psychiatry Joint Annual Meeting. Toronto, Canada, 18-23 October 2005.
56. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J. Psychopharmacol. 23(4), 419-427 (2009).
57. Bright GM, Delphia B, Wildberger B. Survey evaluation of the abuse potential of prescription stimulants among patients with ADHD. Presented at: The 160th Annual Meeting of the American Psychiatric Association. San Diego, CA, USA, 19-24 May 2007.
58. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 84, 135-143 (2006). (Pubitemid 44160579)
59. Winhusen TM, Lewis DF, Riggs PD et al. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 21(5), 455-463 (2011).
60. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W et al. Prevalence of attention-deficit hyperactivity disorder in substance-use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 122(1-2), 11-19 (2012). Excluding nicotine as a primary drug of abuse, this recent meta-analysis of 29 studies suggests ADHD is present in almost one of every four patients with substance-use disorder.
61. Riggs PD, Thompson LL, Mikulich SK, Whitmore EA, Crowley TJ. An open trial of pemoline in drug dependent delinquents with attention deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 35(8), 1018-1024 (1996). (Pubitemid 26266332)
62. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J. Clin. Psychiatry 59(6), 300-305 (1998). (Pubitemid 28353978)
63. Riggs P, Leon S, Mikulich S, Pottle L. An open trial of bupropion for ADHD in adolescents with substance-use disorders and conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 37(12), 1271-1278 (1998). (Pubitemid 28550719)
64. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J. Clin. Psychopharmacol. 21(1), 116-118 (2001). (Pubitemid 32096765)
65. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J. Addict. Dis. 21(2), 1-16 (2002). (Pubitemid 35205006)
66. Somoza EC, Winhusen TM, Bridge TP et al. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J. Addict. Dis. 23(1), 77-92 (2004). (Pubitemid 38437637)
67. Solhkhah R, Wilens TE, Daly J, Prince JB, Van Patten SL, Biederman J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J. Child Adolesc. Psychopharmacol. 15(5), 777-786 (2005). (Pubitemid 41567149)
68. Wilens T, Prince JB, Waxmonsky JG et al. An open trial of sustained release bupropion for attention-deficit/hyperactivity disorder in adults with ADHD plus substance-use disorders. J. ADHD Rel. Disord. 1(3), 25-35 (2010).
69. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A. A randomized controlled trial of pemoline for attentiondeficit/hyperactivity disorder in substanceabusing adolescents. J. Am. Acad. Child Adolesc. Psychiatry 43(4), 420-429 (2004). (Pubitemid 38812382)
70. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substanceuse disorders. Addiction 100(12), 1868-1874 (2005). (Pubitemid 41775212)
71. Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 68(7), 1094-1101 (2007). (Pubitemid 47340332)
72. Szobot CM, Rohde LA, Katz B et al. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance-use disorder. Braz. J. Med. Biol. Res. 41(3), 250-257 (2008). (Pubitemid 351761080)